Xeris Biopharma Director Dawn Halkuff Sells 42,500 Shares at $7.28 Each.

Xeris Biopharma Holdings, Inc. [XERS] has disclosed that Director Halkuff Dawn has recently sold 42,500 shares at a price of $7.28 per share on August 12, 2023.

Xeris Biopharma Holdings, Inc. [XERS] has reported its Q2 2025 earnings, highlighting a significant increase in revenue and a notable turnaround in earnings before interest, taxes, depreciation, and amortization (EBITDA). The company's adjusted loss per share improved from $(0.10) in the prior-year period to $(0.01), beating analysts' expectations of $(0.028) [3].

Revenue (GAAP) jumped 48.8% year over year to $71.5 million, surpassing GAAP estimates by $7.1 million. The full-year 2025 total revenue guidance was raised to $280–$290 million, reflecting strong commercial momentum and confidence in the company's pipeline and product portfolio [3].

The company's adjusted EBITDA turned positive at $12.5 million, a substantial turnaround from a negative figure in the prior year. This positive EBITDA was driven by the continued rapid growth of Recorlev, Xeris's lead therapy for Cushing’s syndrome, which saw net revenue increase approximately 136% year-over-year [3].

In addition to the strong financial performance, Xeris reported that Director Halkuff Dawn has recently sold 42,500 shares at a price of $7.28 per share on August 12, 2023 [2]. This sale follows previous insider trading activities, including purchases by Steven Pieper, who owns 1.4 million shares of XERS stock [2].

The company's stock has been performing well, with shares rising by 17.6% this quarter and gaining 61.9% so far this year. The mean earnings estimate of analysts has risen by about 40.2% in the last three months, and the current average analyst rating on the shares is "buy" [1].

Xeris Biopharma specializes in making injectable drugs more accessible and user-friendly, largely through its proprietary formulation technologies. Its core commercial products are Recorlev, Gvoke, and Keveyis. The company's business model depends heavily on successful commercialization of its therapies, continued growth in patient adoption, and expansion driven by its XeriSol and XeriJect formulation technologies [3].

Looking ahead, Xeris projects ongoing positive adjusted EBITDA (non-GAAP) and expects to achieve a total revenue target of $750 million by 2030. The company's long-term ambitions include Recorlev approaching $1 billion in annual net revenue by 2035 and XP-8121 positioned as a future $1–$3 billion peak net revenue product [3].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2O4:0-xeris-biopharma-holdings-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.quiverquant.com/insiders/1875714/Pieper-Steven
[3] https://www.nasdaq.com/articles/xeris-xers-q2-revenue-jumps-49